Yazar "Karadeniz, Ahmet" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • Küçük Resim Yok
    Öğe
    Pancreas is an Unusual Initial Metastatic Site of Intracranial Hemangiopericytoma
    (Kare Publ, 2016) Ibis, Kamuran; Saynak, Mert; Yalta, Tulin; Ibis, Cem; Kocak, Zafer; Karadeniz, Ahmet
    Intracranial hemangiopericytoma (HPC) is rare and aggressive tumor with local recurrences as well as distant metastases. The majority of metastases are encountered in bone, lung, and liver. Pancreatic metastasis is extremely rare. Described in the present report is the case of a 41-year-old woman who had undergone surgical resection of intracranial HPC 16 years earlier. The tumor recurred 3 years after the operation and was successfully managed with surgery followed by adjuvant radiotherapy. Thirteen years later, an isolated pancreatic metastasis developed. Patient underwent Whipple procedure for pancreatic head lesion and received adjuvant radiotherapy. Patient died of extensive disease in lungs, bones, mediastinum, cranium and peritoneal carcinomatosis in abdomen 17 months after pancreatic surgery.
  • Küçük Resim Yok
    Öğe
    RADIOTHERAPY AS THE PRIMARY AND PALLIATIVE TREATMENT FOR PATIENTS AGED 75 AND OVER WITH LOCALLY ADVANCED AND METASTATIC NON-SMALL CELL LUNG CANCER: ANALYSIS OF 45 CASES WITH A REVIEW OF THE LITERATURE
    (Marmara Univ, Fac Medicine, 2008) Aksu, Gorkem; Fayda, Merdan; Saynak, Mert; Saglamer, Esra Kaytan; Oral, Ethem Nezih; Kizir, Ahmet; Karadeniz, Ahmet
    Aim: To evaluate the prognostic factors and treatment results of Turkish patients aged 75 and over with locally advanced and metastatic non-small cell lung cancer (NSCLC). Patients and Methods: Forty-five patients >= 75 years were evaluated. The median age was 78 (75-93). Thirty-four patients (75%) had stage IIIB and 11 patients had stage IV disease (25%). Fourteen patients (41%) with stage IIIB disease were treated with curative radiotherapy (RT), 18 patients (52%) with palliative RT and 2 patients (5%) were treated with only chemotherapy (CT). Results: The one-year survival rate was 37%. The overall median survival was 12.7 months in stage IIIB and 7.67 months in stage IV. In univariate analysis, advanced stage (p=0.0006), performance status (p=0.056), absence of radiotherapy (p=0.0008) and weight loss (p=0.0053) adversely affected survival. In multivariate analysis only stage IV was found to be a statistically significant independent poor prognostic factor (p=0.0025 HR=0.2760 (0.12-0.60) 95% confidence interval). Conclusion: In Turkish patients, with NSCLC, aged 75 or over, stage IV disease was associated with poor prognosis. The higher radiotherapy doses did not improve survival in patients with stage IIIB disease and the prognosis with only radiotherapy is similar to the results of chemoradiation in the literature in this age group.
  • Küçük Resim Yok
    Öğe
    Radiotherapy as the primary and palliatıve treatment for 75 years and older patients with locally advanced and metastatic non-small cell lung cancer: Analysis of 45 cases wıth a review of the literature
    (2008) Aksu, Görkem; Fayda, Merdan; Saynak, Mert; Sağlamer, Esra Kaytan; Oral, Ethem Nezih; Kizir, Ahmet; Karadeniz, Ahmet
    Amaç: Lokal ileri veya metastatik KHDAK tanılı hastalarda prognostik faktörler ve tedavi sonuçlarının değerlendirilmesi Hastalar ve Metod: 75 yaş ve üzeri toplam 45 KHDAK tanılı hasta değerlendirildi. Medyan yaş 78 idi (75-93). Otuz dört hasta Evre IIIB (75%), 11 hasta (25%) ise Evre IV olarak evrelendirildi. Evre IIIB tanılı hastaların 14 tanesine (41%) küratif Radyoterapi (RT), 18 hastaya (52%) palyatif RT uygulanırken, 2 hasta (5%) sadece kemoterapi (KT) aldı.Bulgular: Bir yıllık genel sağkalım oranı %37 olarak tespit edildi. Medyan sağkalım; Evre IIIB hastalarda 12.7 ay olarak bulunurken, Evre IV hastalarda 7.67 ay olarak gözlendi. Tek değişkenli analizde, ileri evre (p= 0.0006), performans durumu (p=0.056), RT uygulanmaması (p=0.0008) ve kilo kaybı (p=0.0053) sağkalımı olumsuz olarak etkileyen faktörler olarak tespit edildi. Çoklu değişkenli analizde ise; sadece Evre IV hastalık, anlamlı kötü prognostik faktör olarak bulundu (p=0.0025 HR=0.2760 (0.12-0.60) 95% güvenlik aralığı).Sonuç: ? 75 yaş KHDAK tanılı Türk hastalarda, evre IV hastalığın kötü prognozla ilişkili olduğu saptandı. Evre IIIB hastalıkta ise, küratif RT dozlarının sağkalımı iyileştiremediği ancak, tek başına RT ile elde edilen sağkalımın, bu yaş hasta grubunda literatürde kemoradyoterapi ile elde edilen sonuçlara benzer olduğu tespit edildi.